Skip to main content
micro-community-banner
 
  • Saved

Commented on 's Post

Role of FDG PET in the staging of multiple myeloma - PubMed

18 F-Fluorodeoxyglucose (FDG) PET has been used for staging of hematologic malignancies for years. In multiple myeloma, this imaging modality can be used in many different scenarios, including initial staging, ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33813607/

Show More Comments

  • 3 weeks 3 days
    A nice comprehensive review of pet in plasma cell dyscrasias. Overall this modality has taken on an increasing important role in the care of these patients in the last Show More
  • Saved

Commented on 's Post

Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial - PubMed

doi: 10.1111/bjh.17435. Online ahead of print. 1 Vejle Hospital and University of Southern Denmark, Vejle, Denmark. 2 National and Kapodistrian University of Athens School of Medicine, Athens, Greece. 3 Institut ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33822368/

Show More Comments

  • 3 weeks 3 days
    This research is consistent with many other HRQOL studies by showing that this parameter is improved in patients with better disease control
  • Saved

Commented on 's Post

Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population - PubMed

Despite improvements in therapy, approximately 5% of patients who undergo autologous stem cell transplantation (ASCT) experience early mortality (EM), death within 1 year of transplant (EM post-ASCT). Such patients tend ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33814336/

Show More Comments

  • 3 weeks 3 days
    Death within a year of autoSCT not only indicates a disease resistant to chemo but also novel agents given the prolonged pfs of triplet regimens in salvage. These patients Show More
  • Saved

Commented on 's Post

Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design - PubMed

Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received ≥4 prior therapies. Belamaf binds to BCMA and eliminates ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33682447/

Show More Comments

  • 3 weeks 4 days
    This antibody conjugate has intriguing efficacy in a population of patients that has few options ...
  • Saved

Commented on 's Post

Antibody-Based Treatment Approaches in Multiple Myeloma - PubMed

Three monoclonal antibodies (daratumumab, isatuximab, elotuzumab) and one anti-BCMA (B-cell maturation antigen) antibody-drug conjugate (belantamab mafodotin) have been approved by the FDA in the last 5 years for the treatment ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33730360/

Show More Comments

  • 3 weeks 4 days
    There are many more surface targets that have been identified in myeloma beyond cd38, slamf1, and bcma which is extremely exciting for the future of myeloma care
  • Saved

Commented on 's Post

Autologous hematopoietic transplantation following COVID‐19 infection

Marthilde Brzycki, 1 Robert Richard, 1 , 2 Nicholas Burwick, 1 , 2 Solomon Graf, 1 , 3 , 4 Craig O'Brien, 1 Daniel Wu, 1 , 3 and Thomas ..... see more

Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981617/

Show More Comments

  • 3 weeks 4 days
    An interesting report. More knowledge in this area is needed as clinicians presently face challenging decisions on balancing risks of malignancy and covid without a solid evidence base
  • Saved

Commented on 's Post

Show More Comments

  • 3 weeks 4 days
    An expanded indication for a cd38 antibody, which are in key class of medications in the treatment of myeloma ...
  • Saved

Commented on 's Post

Optic nerve head plasmacytoma as a manifestation of multiple myeloma - PubMed

Extramedullary disease in multiple myeloma is uncommon and associated with a poorer prognosis. Extramedullary disease involving the orbit is even more unusual, with optic nerve involvement being rare. We describe ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33767963/

Show More Comments

  • 3 weeks 4 days
    The head and neck region seems to be a common site of extramedullary myeloma /plasmacytoma involvement for reasons that I’m not sure are well understood
  • Saved

Commented on 's Post

FDA Approves First Cell-Based Gene Therapy for Adult Patients with Multiple Myeloma

The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose disease has ..... see more

Source : https://www.fda.gov/news-events/press-announcements/fda-approves-first-cell-based-gene-therapy-adult-patients-multiple-myeloma

Show More Comments

  • 1 month
    This is a very exciting advance for the field of myeloma and ushers in a new era of treatment Existing treatment algorithms will require modification
  • Saved

made a Post

Targeting SIRT1 to inhibit the proliferation of multiple myeloma cells - PubMed

Multiple myeloma (MM) is the second most common hematopoietic malignancy and remains an incurable disease. Thus, novel drugs and therapeutic methods are required for patients with MM. The present study ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33732382/

  • Saved

made a Post

2020 FDA TIDES (Peptides and Oligonucleotides) Harvest

2020 has been an extremely difficult and challenging year as a result of the coronavirus disease 2019 (COVID-19) pandemic and one in which most efforts have been channeled into tackling ..... see more

Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918236/

  • Saved

made a Post

miR‐17‐3p promotes the proliferation of multiple myeloma cells by downregulating P21 expression through LMLN inhibition

Kangdong Liu Corresponding Author China‐US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China Cancer Chemoprevention International Collaboration Laboratory, ..... see more

Source : https://doi.org/10.1002/ijc.33528

63-Year-Old Female Experiences Slow Relapse

Evelyn, now 63, was diagnosed with multiple myeloma when she was 58. She is a district manager for her company and has ..... see more

Show More Comments

  • 1 month 3 weeks
    Elo or dara or kyprolis + rev or Pom + dex This is a situation I like elo to save bigger guns for a symptomatic relapse Could be Show More
  • 1 month 3 weeks
    Given what we know about safety and efficacy data as well as potential benefits for quality of life outcomes, adding Daratumumab and Dex would have potential clinical benefits as best Show More
  • Saved

made a Post

Proteomics-Based Approach Reveals the Involvement of SERPINB9 in Recurrent and Relapsed Multiple Myeloma

Multiple myeloma (MM) is a common hematological malignancy with poorly understood recurrence and relapse mechanisms. Notably, bortezomib resistance leading to relapse makes MM treatment significantly challenging. To clarify the drug ..... see more

Source : https://pubs.acs.org/doi/abs/10.1021/acs.jproteome.1c00007

  • Saved

made a Post

Latest Developments in Cellular Therapy for Multiple Myeloma - touchONCOLOGY

Multiple myeloma (MM) is a malignant clonal disorder of plasma cells in the bone marrow, and more than 32,000 new cases are expected in the USA each year.1 Many clinical ..... see more

Source : https://doi.org/10.17925/OHR.2021.16.2.111

  • Saved

made a Post

Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma

Multiple myeloma (MM) remains an incurable tumor due to the high rate of relapse that still occurs. Acquired drug resistance represents the most challenging obstacle to the extension of survival ..... see more

Source : https://www.mdpi.com/2073-4409/10/2/439

  • Saved

made a Post

Approaches and Challenges in the Management of Multiple Myeloma in the Very Old: Future Treatment Prospects

The increasing incidence of geriatric patients with multiple myeloma has elevated concerns in clinical practice. While the introduction of novel therapeutic agents has substantially improved outcomes in younger patients with ..... see more

Source : https://www.frontiersin.org/articles/10.3389/fmed.2021.612696/full